Amylyx Pharmaceuticals, Inc.
(NASDAQ : AMLX)

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Pharmaceuticals Major
symbolcompany%chnglast%shortavg$volume
JNJJohnson & Johnson -0.23%170.710.7%$966.95m
ABBVAbbVie, Inc. 1.75%140.461.9%$842.51m
PFEPfizer Inc. 0.53%49.530.9%$829.45m
LLYEli Lilly & Co. 0.47%302.721.1%$749.66m
MRKMerck & Co., Inc. 1.30%88.550.7%$749.54m
BMYBristol-Myers Squibb Co. 2.14%73.671.0%$663.79m
SIGASIGA Technologies, Inc. -5.19%22.090.0%$391.42m
AZNAstraZeneca Plc -1.20%65.241.0%$376.90m
ALNYAlnylam Pharmaceuticals, Inc. 5.24%230.048.1%$253.91m
GSKGSK Plc -0.52%40.360.3%$216.73m
HZNPHorizon Therapeutics Plc 1.01%70.305.4%$199.78m
SGENSeagen Inc. 1.60%178.625.7%$191.76m
NVSNovartis AG 0.48%85.980.2%$174.22m
RGENRepligen Corp. 2.71%252.946.7%$159.97m
NVONovo Nordisk A/S -0.67%102.510.1%$151.88m

Company Profile

Amylyx Pharmaceuticals, Inc. operates as a biopharmaceutical company, which provides disease-modifying solutions for neurodegenerative diseases. The firm focuses on streamlined clinical development and drug discovery. It specializes in developing a proprietary therapeutic for Amyotrophic Lateral Sclerosis (ALS) and other neurodegenerative diseases that target the neuroinflammation and nerve cell death that characterize these disorders. The company was founded by Joshua Cohen and Justin Klee in 2013 and is headquartered in Cambridge, MA.